Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Rhea-AI Summary

Context Therapeutics (Nasdaq: CNTX) announced a poster presentation at the American Association for Cancer Research Annual Meeting 2026, April 17-22 in San Diego. The poster will present preclinical data on CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody for solid tumors.

The poster (Abstract #5392) is scheduled for Tuesday, April 21, 2026, 9:00 a.m.–12:00 p.m. PT in Poster Section 48, Session PO.CL05.12. According to the company, the poster will be available on its Publications page at the start of the session.

Key Figures

Abstract number: 5392 Meeting dates: April 17–22, 2026 Poster session time: April 21, 2026, 9:00 a.m.–12:00 p.m. PT +2 more

5 metrics

Abstract number 5392 AACR 2026 CT-202 poster

Meeting dates April 17–22, 2026 AACR Annual Meeting 2026 in San Diego

Poster session time April 21, 2026, 9:00 a.m.–12:00 p.m. PT CT-202 poster presentation window

Session category Clinical Research AACR 2026 CT-202 poster track

Poster location Poster Section 48 AACR 2026 CT-202 presentation area

Market Reality Check

Price: $2.92 Vol: Volume 604,974 is below 2...

low vol

$2.92 Last Close

Volume Volume 604,974 is below 20-day average of 974,980 (relative volume 0.62x), suggesting a measured reaction. low

Technical Shares at $2.92 are trading above the $1.28 200-day MA and sit 19.34% below the 52-week high, up 495.92% from the 52-week low.

Peers on Argus

CNTX is up 2.1% while key biotech peers are mostly down (e.g., ACET -1.98%, IGMS...

1 Up

CNTX is up 2.1% while key biotech peers are mostly down (e.g., ACET -1.98%, IGMS -2.31%, STRO -3.82%). Only IMMX appears in momentum data with a +5.71% move, indicating this looks more stock-specific than sector-driven.

Historical Context

5 past events · Latest: Feb 09 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 09	Investor conferences	Neutral	-4.8%	Planned participation in multiple investor conferences with webcasts and meetings.
Jan 16	Inducement grants	Neutral	+6.9%	Stock option grants to new employees under Nasdaq inducement rules.
Nov 07	Pipeline conference data	Positive	+4.7%	SITC posters on CT-95 and CT-202 showing early safety and preclinical activity.
Nov 05	Earnings and pipeline	Positive	-5.3%	Q3 2025 results with reduced loss, R&D spend, and pipeline updates including CT-202 plans.
Oct 28	Investor conferences	Neutral	-4.9%	Announcements of November 2025 healthcare conference appearances and webcasts.

Pattern Detected

News tied directly to pipeline progress (e.g., CT-95/CT-202 updates) has previously aligned with positive price moves, while at least one earnings update with seemingly constructive details saw a negative reaction.

Recent Company History

Over the last six months, CNTX has issued a mix of conference participation, pipeline, equity grant, and earnings updates. A Nov 7, 2025 SITC update on CT-95 and CT-202 coincided with a +4.67% move, while a Nov 5, 2025 Q3 2025 report with reduced net loss and runway into 2027 saw a -5.31% reaction. More routine conference announcements in Oct 2025 and Feb 2026 were followed by modest declines. The current AACR poster fits the ongoing narrative of advancing CT-202 from preclinical data toward first-in-human development.

Market Pulse Summary

This announcement highlights a CT-202 poster at AACR 2026, emphasizing preclinical work on a Nectin-...

Analysis

This announcement highlights a CT-202 poster at AACR 2026, emphasizing preclinical work on a Nectin-4 x CD3 TCE and its progression toward first-in-human studies. It follows prior CT-202 visibility at SITC on Nov 7, 2025 and pipeline updates in the Nov 5, 2025 earnings report. Investors may track how these presentations connect to future regulatory filings, the broader T cell engager portfolio, and ongoing governance developments disclosed in recent 8-K filings.

Key Terms

bispecific antibodies, nectin-4, cd3, first-in-human, +1 more

5 terms

bispecific antibodies medical

"advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors"

Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.

nectin-4 medical

"CT-202, a Nectin-4 x CD3 TCE."

A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.

cd3 medical

"CT-202, a Nectin-4 x CD3 TCE."

CD3 is a group of proteins on the surface of T cells, the immune system’s front-line soldiers, that act like a control panel to turn those cells on and off. It matters to investors because many modern therapies work by engaging or blocking CD3 to direct T cells against cancer or dampen harmful immune reactions; success, safety and regulatory approval of CD3-targeting drugs can significantly affect a biotech company’s prospects.

first-in-human medical

"First-in-human development of CT-202"

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

antibody-drug conjugates medical

"Bispecific T-Cell Engagers and Antibody-Drug Conjugates"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

AI-generated analysis. Not financial advice.

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company’s asset, CT-202, a Nectin-4 x CD3 TCE.

Poster Presentation Details:
Title:	Targeting solid tumors with pH-dependent dual-specific TCEs: First-in-human development of CT-202
Abstract Number:	5392
Date and Time:	Tuesday, April 21, 2026, 9:00 a.m. – 12:00 p.m. PT
Session Category:	Clinical Research
Session:	PO.CL05.12 – Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates
Location:	Poster Section 48

For more information and to view the Company’s abstract, visit the AACR Annual Meeting website. The poster will be made available in the Publications section of the Company’s website at the beginning of the poster session.

About CT-202
CT-202 is a Nectin-4 x CD3 TCE bispecific antibody that targets Nectin-4, a cell surface protein that is highly and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate (“ADC”), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment.

About Context Therapeutics^®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context’s goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain AACR presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of the Company’s product candidates, (iii) the likelihood data will support future development, and (iv) the likelihood of obtaining regulatory approval of the Company’s product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics
IR@contexttherapeutics.com

FAQ

When will Context Therapeutics (CNTX) present the CT-202 poster at AACR 2026?

The CT-202 poster is scheduled for Tuesday, April 21, 2026, 9:00 a.m.–12:00 p.m. PT. According to the company, the poster will be displayed in Poster Section 48 during Session PO.CL05.12 and available online in the company Publications section at session start.

What topic will Context Therapeutics (CNTX) cover in AACR 2026 poster #5392?

The poster covers preclinical work on pH-dependent dual-specific TCEs and first-in-human development of CT-202. According to the company, it highlights CT-202, a Nectin-4 x CD3 T cell engager aimed at targeting solid tumors with pH-dependent specificity.

Where can investors view Context Therapeutics' (CNTX) AACR 2026 abstract and poster?

Investors can view the abstract on the AACR Annual Meeting website and the poster on the company Publications page. According to the company, the poster will be posted on its website at the beginning of the poster session on April 21, 2026.

What is CT-202, the asset Context Therapeutics (CNTX) is presenting at AACR 2026?

CT-202 is described as a Nectin-4 x CD3 T cell engaging bispecific antibody for solid tumors. According to the company, the poster presents preclinical data supporting CT-202's pH-dependent dual-specific TCE design and first-in-human development rationale.

Which AACR 2026 session will include Context Therapeutics' (CNTX) poster on CT-202?

The poster appears in Session PO.CL05.12: Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates. According to the company, it will be part of the Clinical Research category in Poster Section 48 on April 21, 2026.